Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
VNDA's Cash to Debt is ranked higher than
91% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: 16.07 vs. VNDA: No Debt )
VNDA' s 10-Year Cash to Debt Range
Min: 209.57   Max: No Debt
Current: No Debt

Equity to Asset 0.01
VNDA's Equity to Asset is ranked higher than
51% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. VNDA: 0.01 )
VNDA' s 10-Year Equity to Asset Range
Min: 0.01   Max: 0.32
Current: 0.01

0.01
0.32
Interest Coverage No Debt
VNDA's Interest Coverage is ranked higher than
90% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. VNDA: No Debt )
VNDA' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 2
Z-Score: -4.58
M-Score: -0.08
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -129.96
VNDA's Operating margin (%) is ranked higher than
66% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -55.17 vs. VNDA: -129.96 )
VNDA' s 10-Year Operating margin (%) Range
Min: -28023.53   Max: 24.75
Current: -129.96

-28023.53
24.75
Net-margin (%) -129.63
VNDA's Net-margin (%) is ranked higher than
66% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -51.98 vs. VNDA: -129.63 )
VNDA' s 10-Year Net-margin (%) Range
Min: -27864.71   Max: 20.14
Current: -129.63

-27864.71
20.14
ROE (%) -241.25
VNDA's ROE (%) is ranked higher than
52% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: -25.77 vs. VNDA: -241.25 )
VNDA' s 10-Year ROE (%) Range
Min: -221.21   Max: 23.67
Current: -241.25

-221.21
23.67
ROA (%) -48.29
VNDA's ROA (%) is ranked higher than
62% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: -19.98 vs. VNDA: -48.29 )
VNDA' s 10-Year ROA (%) Range
Min: -176.39   Max: 3.28
Current: -48.29

-176.39
3.28
ROC (Joel Greenblatt) (%) -2560.50
VNDA's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 930 Companies
in the Global Biotechnology industry.

( Industry Median: -210.62 vs. VNDA: -2560.50 )
VNDA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4993.01   Max: 784.55
Current: -2560.5

-4993.01
784.55
Revenue Growth (%) -3.60
VNDA's Revenue Growth (%) is ranked higher than
73% of the 653 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. VNDA: -3.60 )
VNDA' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 89.7
Current: -3.6

0
89.7
» VNDA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

VNDA Guru Trades in Q3 2013

Steven Cohen 66,500 sh (New)
Jean-Marie Eveillard Sold Out
Jim Simons 256,600 sh (-27.54%)
» More
Q4 2013

VNDA Guru Trades in Q4 2013

Jim Simons Sold Out
Steven Cohen Sold Out
» More
Q1 2014

VNDA Guru Trades in Q1 2014

John Paulson 1,392,500 sh (New)
» More
Q2 2014

VNDA Guru Trades in Q2 2014

John Paulson 3,200,000 sh (+129.8%)
» More
» Details

Insider Trades

Latest Guru Trades with VNDA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2014-06-30 Add 129.8%0.12%$9.7 - $16.96 $ 12.12-9%3200000
John Paulson 2014-03-31 New Buy0.11%$10.5 - $18.71 $ 12.12-14%1392500
Jean-Marie Eveillard 2013-09-30 Sold Out 0.02%$8.05 - $13.031 $ 12.1213%0
Jean-Marie Eveillard 2013-06-30 Reduce -48.99%0.01%$3.93 - $13 $ 12.1280%975000
Jean-Marie Eveillard 2012-12-31 Add 43.16%0.01%$3.03 - $4.16 $ 12.12242%1911452
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Vanda Pharmaceuticals Inc

John Paulson's 4 Stocks Trading for Less Than He Paid for Them
John Paulson (Trades, Portfolio)’s firm Paulson & Co. manages approximately $21.4 billion and focuses specifically on arbitrage strategies, restructurings and other capital events. When his team analyzes stocks undergoing corporate events or sectors in which they have interest, they employ a bottom-up assessment of fundamentals within those targets. Read more...

Ratios

vs
industry
vs
history
P/B 403.67
VNDA's P/B is ranked higher than
56% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 5.60 vs. VNDA: 403.67 )
VNDA' s 10-Year P/B Range
Min: 3.56   Max: 540.33
Current: 403.67

3.56
540.33
P/S 9.37
VNDA's P/S is ranked higher than
80% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 19.97 vs. VNDA: 9.37 )
VNDA' s 10-Year P/S Range
Min: 2.62   Max: 69.06
Current: 9.37

2.62
69.06
EV-to-EBIT -6.26
VNDA's EV-to-EBIT is ranked higher than
61% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. VNDA: -6.26 )
VNDA' s 10-Year EV-to-EBIT Range
Min: -1288.6   Max: 578.2
Current: -6.26

-1288.6
578.2
Current Ratio 1.67
VNDA's Current Ratio is ranked higher than
60% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. VNDA: 1.67 )
VNDA' s 10-Year Current Ratio Range
Min: 1.67   Max: 18.62
Current: 1.67

1.67
18.62
Quick Ratio 1.64
VNDA's Quick Ratio is ranked higher than
64% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 3.81 vs. VNDA: 1.64 )
VNDA' s 10-Year Quick Ratio Range
Min: 1.64   Max: 18.62
Current: 1.64

1.64
18.62

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.36
VNDA's Price/Median PS Value is ranked higher than
77% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 1.92 vs. VNDA: 1.36 )
VNDA' s 10-Year Price/Median PS Value Range
Min: 0.46   Max: 9.62
Current: 1.36

0.46
9.62
Earnings Yield (Greenblatt) -16.00
VNDA's Earnings Yield (Greenblatt) is ranked higher than
60% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. VNDA: -16.00 )
VNDA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 3521.3
Current: -16

0.2
3521.3
Forward Rate of Return (Yacktman) 3.45
VNDA's Forward Rate of Return (Yacktman) is ranked higher than
92% of the 767 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. VNDA: 3.45 )
VNDA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -21.3   Max: 11
Current: 3.45

-21.3
11

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:VM4.Germany
Vanda Pharmaceuticals Inc. was incorporated in Delaware in 2002. It is a biopharmaceutical Company focusing on the development and commercialization of clinical-stage drug candidates for central nervous system disorders, with worldwide commercial rights to two product candidates in clinical development. Its partnered products in clinical development include FanaptTM (Oral), FanaptTM (Injectable) Tasimelteon. FanaptTM is a compound for the treatment of schizophrenia. The Company's product portfolio includes: Iloperidone, a compound for the treatment of schizophrenia; and Tasimelteon, a compound for the treatment of sleep and mood disorders, including Circadian Rhythm Sleep Disorders. Tasimelteon binds selectively to the brain's melatonin receptors, which are thought to govern the body's natural sleep/wake cycle. Compounds that bind selectively to these receptors are thought to be able to help treat sleep disorders, and additionally are believed to offer potential benefits in mood disorders. Government authorities in the U.S., at the federal, state and local level, as well as foreign countries and local foreign governments, regulate the research, development, testing, manufacture, labeling, promotion, advertising, distribution, sampling, marketing, import and export of its products.
» More Articles for VNDA

Headlines

Articles On GuruFocus.com
John Paulson's Stocks Trading for Less Than He Paid for Them Jun 02 2014 
Best Performing Gurus of Past Six Months are John Paulson, First Eagle and Michael Price Jun 11 2013 
comment on VNDA Nov 12 2012 
Vanda: This Company Has Great Assets But No Profits Jan 21 2012 
Vanda Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 10 2011 
$VNDA New study started: Oct 15 2010 
Hourly trend UP Aug 11 2010 
Vanda Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 
upgraded to BUY Jul 07 2010 
Vanda Pharmaceuticals Inc. Reports Operating Results (10-Q) May 10 2010 

More From Our Partners
Notable earnings before Monday’s open Oct 26 2014 - SEEKINGALPHA

More From Other Websites
Nasdaq stocks posting largest percentage increases Oct 30 2014
10-Q for Vanda Pharmaceuticals, Inc. Oct 29 2014
VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Oct 29 2014
Vanda Pharmaceuticals Inc. Prices Public Offering of Common Stock Oct 29 2014
9:02 am Vanda Pharma prices 5 mln share public offering at $11.60 Oct 29 2014
Vanda Pharmaceuticals Inc. Prices Public Offering of Common Stock Oct 29 2014
Vanda Pharmaceuticals Inc. Proposes Public Offering of Common Stock Oct 28 2014
VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 28 2014
Vanda Pharmaceuticals Inc. Proposes Public Offering of Common Stock Oct 28 2014
Twitter Takes A Tumble As Ability To Innovate Comes Into Question Oct 28 2014
S&P 500 trades in a narrow range, up against key technical levels Oct 27 2014
Vanda Pharmaceuticals Inc Earnings Call scheduled for 10:00 am ET today Oct 27 2014
Vanda Pharmaceuticals Reports Third Quarter 2014 Financial Results Oct 27 2014
Vanda Pharmaceuticals Reports Third Quarter 2014 Financial Results Oct 27 2014
VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Oct 27 2014
Q3 2014 Vanda Pharmaceuticals Inc Earnings Release - Before Market Open Oct 27 2014
Vanda Pharmaceuticals to Announce Third Quarter 2014 Financial Results on October 27, 2014 Oct 14 2014
VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in... Sep 22 2014
VANDA PHARMACEUTICALS INC. Financials Aug 15 2014
VANDA PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly Report Aug 08 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK